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Abstract
Background: hyaluronic acid (HA), a non-sulphated glycosaminoglycan, is present in synovial fluid, vitreous
humour serum and many connective tissues. Pharmaceutical preparations of HA are used in clinical practice for
wound healing, joint pain, kerato-conjunctivitis, asthma, mouth care, oesophageal-reflux, and gastritis. Moreover, it
is used as a filler to counteract ageing and facial lipoatrophy. Our study aims at investigating the in vitro antiviral
activity of a high molecular weight HA.
Methods: the MTT test was used to rule out the potential toxic effects of HA on the different cell lines used in the
antiviral assays. The antiviral activity of HA against Coxsackievirus B5, Herpes Simplex Virus-1, Mumps Virus,
Adenovirus-5, Influenza Virus A/H1N1, Human Herpesvirus-6, Porcine Parvovirus, Porcine Reproductive and
Respiratory Syndrome Virus was assessed by virus yield assays.
Results: the most effective inhibition was observed against Coxsackievirus B5, with 3Log reduction of the virus
yield at 4 mg/ml, and a reduction of 3.5Log and 2Log, at 2 mg/ml and 1 mg/ml, respectively: the selectivity index
was 16. Mumps virus was highly inhibited too showing a reduction of 1.7Log at 1 mg/ml and 1Log at 4 mg/ml
and 2 mg/ml (selectivity index = 12). The selectivity index for Influenza Virus was 12 with the highest inhibition
(1Log) observed at 4 mg/ml. Herpes Simplex Virus-1 and Porcine Parvovirus were mildly inhibited, whereas no
antiviral activity was observed with respect to Adenovirus-5, Human Herpesvirus-6, Porcine Reproductive and
Respiratory Syndrome Virus. No HA virucidal activity was ever observed against any of the viruses tested. Kinetic
experiments showed that both Coxsackievirus B5 and Herpes simplex virus-1 replication were consistently inhibited,
not influenced by the time of HA addition, during the virus replication cycle.
Conclusions: the spectrum of the antiviral activity exhibited by HA against both RNA and DNA viruses, known to
have different structures (with or without envelope) and replication strategies, suggests a non specific mechanism
of action, probably involving cell membrane-virus interaction steps. The results of the kinetic experiments support
this hypothesis.
Introduction
Hyaluronic acid (HA) is a non-sulphated glycosaminogly-
can which consists of alternately repeating D-glucuronic
acid and N-acetylglucosamine units. A huge variety of
HAs, with different molecular weights, has been
described, probably retaining distinct physicochemical
and biological properties. HA is naturally present
throughout all mammalian systems, especially synovial
fluid, vitreous humour serum and many connective tis-
sues [1]. Moreover, HA is found intercellularly in con-
nective tissues, such as skin, combined with proteins and
chondroitin sulphate, where it fulfills important functions
involved in tissue structure maintenance, moisture and
lubrication [2].
Initially introduced in clinical practice as wound heal-
ing promoter, HA is currently used in many medical
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and cosmetic fields. Some examples of HA applications
include eye drops for kerato-conjunctivitis, intra-articu-
lar injections for osteoarthritic joint pain, irrigations for
bladder and vaginal chronic inflammatory disorders, tra-
cheobronchial aerosolization for asthma, oral solutions
for mouth care or for oesophageal-reflux and gastritis.
Besides, HA is commonly used for cosmetic interven-
tions, as a filler to counteract ageing and facial lipoatro-
phy, especially in HIV patients [3].
There is evidence showing the ability of HA to inter-
fere with viral replication in vitro. In particular, the
replication of Herpes Simplex Virus type 2 [4], Respira-
tory Syncytial virus [5] and retroviruses [6] is inhibited
by HA, while the Adenovirus (ADV) one results
enhanced [7]. Such limited and apparently controversial
data demand further investigations in order to better
understand the HA biological properties.
In this study we investigated the in vitro effects of a
high molecular weight HA against a wide group of
viruses covering a large spectrum of structural features
and replication strategies: ADV-5, Coxsackievirus B5
(COXB5), Herpes Simplex Virus type 1 (HSV-1),
Human Herpesvirus-6 (HHV-6), Influenza Virus A/
H1N1, Mumps Virus (MV), Porcine Parvovirus (PPV),
Porcine Reproductive and Respiratory Syndrome Virus
(PRRSV). We observed an antiviral activity against
COXB5, HSV-1, MV, PPV and Influenza Virus encoura-
ging the use of such compound as a medical tool in spe-
cific clinical circumstances.
Materials and methods
Hyaluronic Acid
A high molecular HA (1.800 KD) in powder (IBSA, Istituto
Biochimico SA, Lugano, CH) was used. It was dissolved in
Minimum Essential Medium (EMEM) at 8 mg/ml solution
and sterilized by filtration through 0.45 μm filters.
Cells and Viruses
The following cell lines were used to cultivate the differ-
ent viruses: two monkey kidney lines, VERO cells for
ADV-5, COXB5, HSV-1, and MV and MARC145 cells
for PRRSV; the human T-leukaemia lymphoblast line
JJHAN for HHV-6; the canine kidney line MDCK for
Influenza Virus; the pig cell line PK15 for PPV. VERO,
MARC145, PK15 and MDCK cells were cultured in
EMEM added with 10% (growth medium) or 5% (main-
tenance medium) foetal bovine serum (FBS), penicillin
(100 U/ml) and streptomycin (100 μg/ml); RPMI 1640
medium supplemented with 10% heat-inactivated FBS,
penicillin (100 U/ml) and streptomycin (100 μg/ml) was
used for JJHAN cells. All the cell lines were incubated
at 37°C with 5% CO2.
The viral strains of HSV-1, ADV-5, COXB5 and MV
were clinical isolates, laboratory adapted through serial
passages (>50) on VERO cells. The Influenza Virus
strain used was the highly neurotropic cell culture
adapted WSN33 strain (A/H1N1). For HHV-6, the
U1102 strain (variant A) was employed, whereas the two
swine viruses tested were reference strains: NADL-2 for
PPV and the ATCC strain (Cat. N° VR-2402) for
PRRSV. Batches of each virus were prepared, titrated on
the suitable cell line and kept frozen at -80°C until they
were used for the experiments.
Cytotoxicity Assay
The MTT test [8] was used to evaluate the effects of the
different concentrations of HA on cell viability. Briefly,
serial dilutions of HA from 4 mg/ml to 0.5 mg/ml were
prepared in maintenance medium and added (250 μl/
well) to 24 hr-old cultures of each line. Each dilution
was always tested in triplicate and, in each of the 3
experiments carried out, 3 control wells were included.
The plates, with the different cell lines, were incubated
at different times: 24 hrs for VERO cells, 48 hrs for
MDCK and MARC 145 cells, 72 hrs for PK15 cells and
6 days for JJHAN cells. After incubation with HA, the
MTT staining was carried out as previously described
[9]. Cell viability was calculated as a percentage of the
optical density (OD) of the HA-treated cultures in com-
parison with that one of the untreated controls (100%
viability).
Assay of Cell Protection from Lysis
Twenty-four hour growth VERO and MDCK cells in 96
well plates were exposed for 1 h to HA (4 mg/ml); then
a cell lysis solution Triton X-100 was added to each
well at a final concentration of 0.1% and 0.5%. After 5’
for 0.1% concentration and 15’ for 0,5% concentration,
the lysis solution was removed and replaced with fresh
medium. The cell viability was measured by MTT test
and the survival of HA treated cells was compared with
that one of HA untreated cultures. In each assay, cells,
not exposed to lysis solutions, were used as controls
(100% viability). Three experiments were carried out,
each one with samples in triplicate.
Antiviral Assays
The antiviral activity was ascertained by means of virus
yield assays. Twenty-four hour growth cell cultures were
infected with the different viruses at the following multi-
plicity of infection values: for COXB5, ADV-5 and MV
0.1Tissue Culture Infectious Dose 50% (TCID50)/cell;
for HSV-1, 0.1 Plaque Forming Unit (PFU)/cell; for
WSN33 virus, 0.1 PFU/cell; for PPV, 0.1 TCID50/cell;
for PRRSV, 0.1 TCID50/cell; for HHV-6, 0.1 TCID50/
cell. After 1 hr adsorption at 37°C, the inoculum was
removed, the plates washed with PBS and the different
dilutions of HA, in maintenance medium, added to the
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cell cultures (each HA dilution was tested in triplicate).
After 24 hr incubation for COXB5, ADV-5, MV and
HSV-1, 48 hr for WSN33 and PRRSV, 72 hr for PPV
and 6 days for HHV-6 the plates were frozen and
thawed three times and the viral yield was titrated by
end-point titration for ADV, COXB5, MV, PPV, PRRSV,
and HHV-6 and by plaque assay for HSV-1 and
WSN33. As far as end-point titration is concerned, 10-
fold dilutions of each cell lysate were seeded on the 24
hr growth cells in a 96-well culture plate. After 3 days
(6 days for HHV-6), the viral titre of each sample,
expressed as TCID50/ml, was read taking into account
the final dilution still showing the typical viral cyto-
pathic effect and the results were elaborated using the
Reed and Muench formula [10]. Plaque assays were car-
ried out as follows. The samples from the HSV-1 and
WSN33 experiments, serially diluted in 10-fold dilutions,
were seeded on 24 hr growth VERO or MDCK cells in
24 well plates. After 1 hr adsorption, the viral inoculum
was removed, the plates were washed with PBS and the
maintenance medium, containing 0.9% Noble Agar, was
added. After 72 hr incubation, the plates were stained
with Neutral Red and the plaques counted: the resulting
titre was expressed as PFU/ml. The selectivity index (SI)
was calculated for each virus inhibited by HA as the
ratio between the toxic dose 50 and the inhibiting dose
50. For each virus 3 experiments were carried out.
Effects on the Antiviral Activity of Adding HA at Different
Time Points
Time course experiments were carried out with COXB5
and HSV-1 within a single replication cycle. HA (2 mg/
ml) was added, at different time points, within 7 hr for
COXB5 and 18-20 h for HSV-1 according to each viral
replication cycle. In parallel wells, HA was added
together with the viral inoculum (t = 0). The virus yield
was assessed by end point titration (for COXB5) or pla-
que assay (for HSV-1). For each virus, 3 experiments
were carried out, each in duplicate.
Virucidal Activity Assays
The different viral inocula were exposed to HA at a final
concentration of 4 mg/ml, for 30’ at room temperature
and then their residual infectivity was titrated on the
suitable cells, as described above. A viral inoculum, trea-
ted with medium without HA was used as control for
each virus. Two experiments for each virus were per-
formed, each in duplicate.
Results
Lack of Cytotoxicity Cell protection from lysis
Initially, in order to rule out any direct cytotoxic effect of
HA, dose-dependent experiments were performed expos-
ing the five cell lines, employed in the experiments, to
HA for different times (1 to 6 days, according to the
protocols used for virus growth) followed by MTT
assay. We found modest cytotoxicity only at the high-
est HA concentration (4 mg/ml) which caused a OD
reduction of about 20% in 4 of the 5 tested cell lines
(Figure 1). At the lower concentrations, the OD reduc-
tion was about 10% or less. A slightly higher OD
reduction (about 30%) was observed on JJHAN cells at
4 mg/ml, probably related to the longer exposition to
HA of this cell line (6 days vs 1-3 days for the other
cells).
Cell Protection from Lysis
With the aim of investigating whether HA may affect
cell membrane stabilization, experiments, in which
VERO and MDCK cells were pre-treated with HA and
then exposed to a lysis solution (Triton X-100) were
carried out. We found that both cell lines pre-treated
for 1 hr with HA at 4 mg/ml were significantly more
resistant to lysis than the untreated controls. In particu-
lar, for VERO cells in the HA pre-treated groups, the
cell viability was close to 100% with the mild treatment
(0.1% for 5’) and 24.4% with the stronger one (0.5% for
15’), whereas in parallel groups, not pre-exposed to HA
before lysis, the cell viability was reduced to 68.1% and
15.2%, respectively (Figure 2). MDCK cells were more
sensitive to lysis treatment, but also in this case the cells
pre-treated with HA were more resistant to cell lysis
(38,2% and 21.1% the cell viability for the milder and
the stronger treatment, respectively) than those not
exposed to HA (30.4% and 10.1%).
Antiviral Activity by HA
Virus yield experiments were carried out in the presence
of HA to assess its antiviral activity. As shown in Figure
3A, HA exerted the most effective inhibition towards
COXB5, with 3Log reduction of the virus yield at 4 mg/
ml, and reduction of 3.5Log and 2Log at 2 mg/ml and 1
mg/ml, respectively. This strong inhibition was also con-
firmed by the SI (Appendix 1) which was 16.1. MV and
Influenza Virus were highly inhibited too (SI = 12.1 and
11.9, respectively): 1Log at 4 mg/ml and 2 mg/ml, 1.7Log
reduction at 1 mg/ml, for MV (Figure 3B) and about
1Log even at 1 mg/ml for WSN33 (Figure 3E). Two other
viruses were inhibited, although to a lesser extent. HSV-1
and PPV showed 1Log reduction only at 4 mg/ml (Figure
3C and 2F) with lower SIs (4.8 and 3.6, respectively). No
antiviral activity was observed with ADV-5 (Figure 3D),
HHV-6 (Figure 3G) and PRSSV (Figure 3H).
Effects on the Antiviral Activity of Adding HA at Different
Time Points
In order to investigate the timing of HA inhibition on
replication cycle of HSV-1 and COXB5, kinetic
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Figure 1 Twenty-four hour old cell cultures were treated with HA in the maintenance medium and then incubated for different times:
24 hours for VERO cells, 48 hours for MDCK and MARC 145 cells, 72 hours for PK15 cells and 6 days for JJHAN cells. Then, the MTT
assay was performed. Cell viability was calculated as the percentage of optical density of the HA-treated cultures in comparison with that one of
untreated controls (100% viability).
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Figure 2 VERO and MDCK cells, pre-treated or not with HA, were exposed to Triton X-100 at 0.1% and 0.5% concentration for 5’ and
15’, respectively; then, the cell viability was assessed by MTT assay. * p < 0.05 with the Student’s t test in comparison with HA untreated
controls.
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Figure 3 Different cell lines were infected with COXB5 (panel A), MV (panel B), HSV-1 (panel C), ADV-5 (panel D), WSN33 (panel E),
PPV (panel F), HHV-6 (panel G), PRRSV (panel H) and then exposed to HA at different concentrations in the maintenance medium. The
virus yield was titrated by end point titration for COXB5, MV, ADV-5, PPV, HHV-6 and PRRSV (results expressed as Log of the TCID50) and by
plaque assay for HSV-1 and WSN33 (results expressed as PFU/ml). * p < 0.05 with the Student’s t test in comparison with HA untreated controls.
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experiments were designed. HA was added to the
infected cells at different time points, during a single
replication cycle. Both COXB5 (Figure 4A) and HSV-1
(Figure 4B) growth were consistently inhibited by HA,
regardless of the time of addition.
Lack of HA Direct Virucidal Activity
With the aim to assess whether HA could directly inac-
tivate virus particles, each viral inoculum was resus-
pended with HA for 30 minutes before cell infection.
The results of these experiments showed that the virus
titre was not significantly reduced (<0,5Log) after HA
treatment, indicating no virucidal activity by HA against
any of the tested viruses (data not shown).
Discussion
This paper provides a new information on the biological
properties of HA, describing its antiviral in vitro activity
against 5 viruses, with different structural and biological
features.
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Figure 4 HA (2 mg/ml) was added at different time points within a single viral replication cycle (7 h for COXB5, 18-20 h for HSV-1). In
parallel wells, HA was added together with the virus inoculum (T = 0). At the end of the replication cycle, cell cultures were frozen and the
virus yield was titrated by end point titration (COXB5, panel A) or plaque assay (HSV-1, panel B). The results are expressed as Log of the TCID50
in panel A, as PFU/ml in panel B. * p < 0.05 with the Student’s t test in comparison with HA untreated controls.
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HA is a non-sulfated glycosaminoglycan widely pre-
sent in the extracellular matrix of soft tissues and in
several biologic fluids [2]. Experimental and clinical data
demonstrate the involvement of HA in structure main-
tenance, moisturizing, tissue lubrication and wound
healing. These properties, associated with an excellent
safety profile, are exploited in medical practice as well
as in aesthetic and cosmetic fields [2,3]. Furthermore,
initial evidence also ascribes antimicrobial properties to
HA [11-13], adding further appeal to the HA-containing
products because of the beneficial effects probably deriv-
ing from its antimicrobial properties. Here, we have
demonstrated a wide spectrum antiviral activity of a
high molecular weight HA. The most effective inhibition
is observed against COXB5, MV and Influenza Virus
WSN33 (A/H1N1) and it is interesting that the phe-
nomenon is retained even at a concentration (1 mg/ml)
lower than that one commonly used for clinical or cos-
metic applications. The high SIs displayed by HA for
these viruses document a strong antiviral activity not
related to cytotoxicity. HSV-1 and PPV are also inhib-
ited by HA, but only at the highest concentration (4
mg/ml): the SIs are consequently lower. No activity is
ever observed against ADV-5, HHV-6, PRRSV. The HA
failure to inhibit ADV is not unexpected since, accord-
ing to Chaudhuri [7], HA enhances ADV replication in
vivo and, though to a lesser extent, also in vitro. The dif-
ferent cell system we used may account for the lack of
replication enhancement observed in our experiments.
Our findings provide evidence on the effects of HA on
a variety of RNA and DNA viruses, with or without the
lipidic envelope, characterized by very different replica-
tion strategies. Therefore, we can speculate that HA
antiviral mechanism(s) probably involves general/non-
specific host cell-virus interaction at membrane level,
such as virus entry or release, rather than restricted,
virus-specific events occurring inside the cell. This spec-
ulation is supported by the kinetic results showing that
both COXB5 and HSV-1 are growth inhibited irrespec-
tive of the time of HA addition during the virus replica-
tion cycle. In line with this hypothesis, we may suggest
that HA, known to have a heavy ionic charge, may alter
the electrostatic interactions between virus and cell
receptors and/or other cell membrane components, thus
in turn affecting virus entry and/or exit. Literature data
substantiate this hypothesis. Dengue virus uses heparan-
sulphate (HS) as a cell receptor: different types of HA,
interacting with the virus envelope glycoprotein, respon-
sible for virus attachment to HS, are able to inhibit
virus attachment and entry [14]. HSV-1 recognizes HS
as a receptor too and it has been reported that mole-
cules, affecting the interaction between HSV-1 envelope
glycoproteins and HS, are able to reduce the virus
growth [15-17]. Several Enteroviruses (including some
Coxsackieviruses) are reported to interact with HS for
virus entry [18-20]. The results of our kinetic experi-
ments seem to suggest that virus release is also inhibited
by HA. Notoriously, this step involves host cell mem-
brane. HSV-1 and COXB5 are released by different
mechanisms: HSV-1 by trans-membrane trafficking of
vesicles, while COXB5 by cell membrane lysis. Therefore
we may assume that the mechanism, by which HA inhi-
bits virus release, has to be non-specific. The results
observed in the assay of cell protection from lysis, show-
ing that cells exposed to HA are more resistant to cell
lysis, suggest that HA stabilizes cell membranes. This
modification could impair any membrane involving pro-
cess, such as envelope fusion with cell membrane, vesi-
cle fusion and membrane disruption. We have observed
that in the antiviral experiments with MV, a syncytiogen
virus, not only virus yield was reduced in the presence
of HA, but syncytia size also appeared at light micro-
scope observation smaller than those ones of the control
cultures. This HA stabilizing activity on membranes
indirectly implies that cell exposure to HA inhibits virus
entry and/or exit. Finally, the lack of appreciable viruci-
dal activity by HA, against all the viruses under study,
rules out the possibility of a direct virus inactivation by
HA and it also supports the idea that the steps, invol-
ving virus-cell membrane interaction, are preferentially,
if not exclusively, affected by HA.
In conclusions, our study provides a wide spectrum
demonstration of the antiviral activity by HA, opening
new perspectives in prophylaxis and therapy of some
viral diseases. The hypothesis of specifically counteract-
ing cell-virus attachment and viral release, by local
administration of HA, is very appealing especially for
oral, genital and ano-rectal anatomical areas, where
compound(s) can be administered as creams, gels or
wash solutions. Many HA-based commercial products
already available for topic use have HA concentrations
much higher or equal to those we found active against
different viruses: so it can be hypothesized that effective
concentrations can be locally reached. The inhibitory
activity observed against HSV-1 is particularly interest-
ing since HA is the basic component of mouthwash
solutions and ophthalmic drops, used as artificial tears.
According to our findings, HA may be also considered/
included as an antiviral agent in the treatment of HSV-
1-associated stomatitis and kerato-conjunctivitis in this
kind of preparations. Moreover, since Enteroviruses are
often responsible for a childhood form of vesicular sto-
matitis as well as respiratory diseases, the present find-
ings on Coxsackievirus inhibition may open new
perspectives for oral administration of HA as natural
atoxic medical treatment of newborns and babies. Simi-
larly, the anti-influenza virus activity observed might be
exploited in nasal sprays to locally reduce viral
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replication. Moreover, HA has been demonstrated to
have pro-inflammatory activity. Low weight HA frag-
mentation products and, in the presence of IFNg, even
high molecular weight HA molecules can also activate
innate immunity mechanisms through Toll-like Recep-
tor 4 and CD44 [21,22]. This pro-inflamamtory activity
may contribute to counteract virus replication and
spread in vivo.
In conclusion, our findings strongly support the use of
this safe glycosaminoglycan in clinical practice as a
potential antiviral compound, both for disease preven-
tion and treatment. Further clinical trials on this topic
are required to better understand the antiviral activity of
this compound.
Appendix 1 - Selectivity indexes of HA
Coxsackievirus B5 - 16.1
Mumps virus - 12.1
Influenza A/H1N1/WSN33 - 11.9
Herpes Simplex Virus-1 - 4.8
Porcine Parvo - 3.6
Selectivity indexes were calculated for those viruses
inhibited by HA as the ratio between the toxic dose 50
and the inhibiting dose 50.
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